Caffeine Citrate does not reduce brain injury following inflammation-amplified hypoxia ischaemia or hypoxia ischaemia in the Newborn Piglet Model

There is a need to develop alternative therapies for neonatal encephalopathy (NE) in term babies. Caffeine citrate exposure saw benefit in preclinical models of hypoxia-ischaemia (HI). We assessed the safety and cytoprotective efficacy of caffeine citrate in an inflammation-amplified (IA-HI) and HI newborn piglet model based on the probability of treatment superiority (Pr<sub>(sup)</sub>) of magnetic resonance spectroscopy, amplitude integrated encephalography (aEEG/EEG) and immunohistochemistry outcomes. Eighteen newborn piglets were randomised to saline, 20/10/10 mg/kg or 60/30/30 mg/kg caffeine citrate following IA-HI. A further twenty piglets were randomised to saline or 40/10/10 mg/kg caffeine citrate following HI. Caffeine plasma concentrations were within range following a 20/10/10 mg/kg dosage but were lower than putative target levels following a 40/10/10 mg/kg dosage. Caffeine concentrations exceeded toxic levels following a 60/30/30 mg/kg dosage. Following IA-HI, 20/10/10 or 60/30/30 mg/kg caffeine citrate treatment failed to reduce white matter (WM) (Pr<sub>(sup)</sub> 39.3 %, 52.5 %) and basal ganglia and thalamic (BGT) (Pr<sub>(sup)</sub> 35.0 %, 50.3 %) lactate/N-acetylaspartate (Lac/NAA), preserve the phosphocreatine/exchange phosphate pool (PCr/Epp) ratio (Pr<sub>(sup)</sub> 44.2 %, 62.0 %), or improve aEEG/EEG recovery (Pr<sub>(sup)</sub> 22.4 %, 21.7 %). A 60/30/30 mg/kg dose demonstrated increased cell death, indicating toxicity. Following HI, 40/10/10 mg/kg caffeine citrate treatment failed to reduce WM (Pr<sub>(sup)</sub> 58.3 %) and BGT (Pr<sub>(sup)</sub> 48.0 %) Lac/NAA, preserve the PCr/Epp ratio (Pr<sub>(sup)</sub> 72.8 %), or improve aEEG/EEG recovery (Pr<sub>(sup)</sub> 48.0 %), with seizures more refractory. However, there was a modest benefit in male caffeine-treated piglets following HI. The lack of neuroprotection observed following caffeine citrate treatment after both IA-HI and HI suggests further preclinical studies are required before clinical translation for term babies with NE.

Authors

Institutions

Publication Details

Journal
Neuropharmacology
Published
2025-11-06
DOI
https://doi.org/10.1016/j.neuropharm.2025.110763
Primary Topic
Neonatal and fetal brain pathology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Caffeine Citrate does not reduce brain injury following inflammation-amplified hypoxia ischaemia or hypoxia ischaemia in the Newborn Piglet Model

Christopher Meehan, John Barks, George Maple, Nicola Jayne Robertson et al.
Neuropharmacology
Neonatal and fetal brain pathology
article

Caffeine Citrate does not reduce brain injury following inflammation-amplified hypoxia ischaemia or hypoxia ischaemia in the Newborn Piglet Model

Christopher Meehan, John Barks, George Maple, Nicola Jayne Robertson, Alison Mintoft, Ellie Campbell, Raymand Pang, Kennosuke Tsuda, Alan Bainbridge, Louise Han, Jong Seung Kim, Katie Tucker, Francisco Torrealdea, Georgina Norris, Ivana d’Angelo
article en

Abstract

There is a need to develop alternative therapies for neonatal encephalopathy (NE) in term babies. Caffeine citrate exposure saw benefit in preclinical models of hypoxia-ischaemia (HI). We assessed the safety and cytoprotective efficacy of caffeine citrate in an inflammation-amplified (IA-HI) and HI newborn piglet model based on the probability of treatment superiority (Pr<sub>(sup)</sub>) of magnetic resonance spectroscopy, amplitude integrated encephalography (aEEG/EEG) and immunohistochemistry outcomes. Eighteen newborn piglets were randomised to saline, 20/10/10 mg/kg or 60/30/30 mg/kg caffeine citrate following IA-HI. A further twenty piglets were randomised to saline or 40/10/10 mg/kg caffeine citrate following HI. Caffeine plasma concentrations were within range following a 20/10/10 mg/kg dosage but were lower than putative target levels following a 40/10/10 mg/kg dosage. Caffeine concentrations exceeded toxic levels following a 60/30/30 mg/kg dosage. Following IA-HI, 20/10/10 or 60/30/30 mg/kg caffeine citrate treatment failed to reduce white matter (WM) (Pr<sub>(sup)</sub> 39.3 %, 52.5 %) and basal ganglia and thalamic (BGT) (Pr<sub>(sup)</sub> 35.0 %, 50.3 %) lactate/N-acetylaspartate (Lac/NAA), preserve the phosphocreatine/exchange phosphate pool (PCr/Epp) ratio (Pr<sub>(sup)</sub> 44.2 %, 62.0 %), or improve aEEG/EEG recovery (Pr<sub>(sup)</sub> 22.4 %, 21.7 %). A 60/30/30 mg/kg dose demonstrated increased cell death, indicating toxicity. Following HI, 40/10/10 mg/kg caffeine citrate treatment failed to reduce WM (Pr<sub>(sup)</sub> 58.3 %) and BGT (Pr<sub>(sup)</sub> 48.0 %) Lac/NAA, preserve the PCr/Epp ratio (Pr<sub>(sup)</sub> 72.8 %), or improve aEEG/EEG recovery (Pr<sub>(sup)</sub> 48.0 %), with seizures more refractory. However, there was a modest benefit in male caffeine-treated piglets following HI. The lack of neuroprotection observed following caffeine citrate treatment after both IA-HI and HI suggests further preclinical studies are required before clinical translation for term babies with NE.

NeuropharmacologyVol. 283
University of Michigan (US), Royal London Hospital (GB), London Women's Clinic (GB), UCL Biomedical Research Centre (GB), Institute for Reproductive Health (US), University College London (GB)
Openalex Percentile: Top 55%
Neonatal and fetal brain pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.